AHR and cancer: In the present study, we identify AHR pathway activity, a downstream component of IDO/TDO-Kyn axis, as a common feature of cancers expressing IDO or TDO and as a driver of T cell dysfunction by promoting a Treg-macrophage suppressive axis in the TME.